Bioequivalence and Bioavailability Forum

Hi Helmut,

thanks for the comments.
In perspective, could this methodology then be extended to a 3-treatment parallel study (e.g. US Ref, EU Ref, Test)? I am thinking we'd just need another sigma squared on the diagonal and then be good to go? If that's the case then the WNL approach –however counterintuitive and retarded it might seem– could provide a solution to a problem which cannot be resolved by the standard t-test approach?
Oh and by the way, I think this would imply that the denominator DFs would have to be calculated from treatment A, B as well as C, when a 90% CI for A/B is constructed - that's perhaps also worthy of a heated debate further down the road...?